Brainsway Ltd. Stock Price, News & Analysis

BrainsWay (NASDAQ: BWAY) has made a strategic investment in Neurolief, a brain stimulation company developing non-invasive neuromodulation therapies. The investment comes as Neurolief awaits FDA approval for its Proliv™Rx system, designed to treat Major Depressive Disorder (MDD).

The Proliv™Rx system represents a breakthrough in depression treatment, offering at-home brain neuromodulation therapy for patients who haven't responded adequately to traditional antidepressants. BrainsWay's commercial expertise and global presence, with Deep TMS systems in over 1,500 clinics worldwide, positions Neurolief for significant market penetration post-FDA approval.

The partnership aims to address a critical gap in mental health care, particularly for patients who have limited access to clinic-based treatments due to factors such as childcare, employment, or geographical constraints.

BrainsWay (NASDAQ: BWAY) has made a strategic investment in Neurolief Ltd. through a $5 million convertible loan with an option to acquire the company. Neurolief is developing the first wearable, non-invasive, multi-channel brain neuromodulation platform for at-home use.

The agreement includes potential additional milestone-based funding: a $6 million convertible loan upon FDA approval of Neurolief's Proliv Rx system for Major Depressive Disorder (MDD), and a $5 million equity investment upon reaching specific revenue targets. BrainsWay has also secured a call option to acquire Neurolief's outstanding equity during defined exercise windows.

Neurolief's Proliv™Rx device is currently pending FDA Premarket Approval and, if granted, will become the first FDA-cleared medical device for MDD treatment that can be administered outside clinical settings. The company's Relivion®MG therapy is already approved in the U.S., Europe, and Japan for migraine treatment.

BrainsWay (NASDAQ & TASE: BWAY), a leader in noninvasive neurostimulation treatments, has announced a strategic equity investment in Axis Integrated Mental Health, a Colorado-based mental health clinic management services organization. The investment consists of an initial $2.3 million with a potential additional $1 million milestone-based investment for a minority stake in Axis.

This investment follows BrainsWay's previous stake in Stella and aligns with the company's strategy to accelerate access to innovative mental health treatments, including their Deep TMS Therapy. The investment will be structured as a preferred, annually compounding security with a redemption mechanism, enabling Axis to expand its services and grow from a regional platform to a larger footprint.

BrainsWay (NASDAQ: BWAY), a leader in noninvasive neurostimulation treatments, reported strong Q2 2025 financial results. The company achieved record quarterly revenue of $12.6 million, up 26% year-over-year, with a net profit of $2.0 million, representing a 233% increase.

Key operational highlights include shipping 88 Deep TMS™ systems (35% YoY increase), reaching a total installed base of 1,522 systems. The company maintained a strong 75% gross margin and increased Adjusted EBITDA by 16% to $1.5 million. Notably, 70% of new customer engagements are structured as multi-year lease agreements, with remaining performance obligations of $62 million.

Based on strong performance, BrainsWay raised its full-year 2025 guidance to revenues between $50-52 million, with operating income of 4-5% and Adjusted EBITDA of 12-13%. The company also entered a strategic equity financing transaction with Stella MSO, LLC, expanding its mental health provider network.

BrainsWay (NASDAQ:BWAY), a leader in noninvasive neurostimulation treatments, has announced the sponsorship of two free Continuing Medical Education (CME) courses focused on Transcranial Magnetic Stimulation (TMS). The courses, worth 0.5 AMA PRA Category 1 Credits™ each, are led by prominent psychiatry experts.

The first course, presented by Dr. David Feifel, covers evidence-based TMS data and technology distinctions. The second course, led by experts from Brown University, Harvard Medical School, and Sheppard Pratt, focuses on practical patient application strategies. BrainsWay's Deep TMS™ technology is uniquely FDA-cleared for treating depression, anxious depression, late-life depression, OCD, and smoking addiction.

BrainsWay (NASDAQ & TASE: BWAY), a leader in noninvasive neurostimulation treatments for mental health disorders, has scheduled its second quarter 2025 financial results announcement for August 13, 2025, before U.S. markets open.

The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss financial results and operational highlights. The call will be accessible via multiple dial-in numbers and will be available for replay on the company's investor relations website for 30 days.

BrainsWay (NASDAQ: BWAY) has announced promising results from a major multicenter randomized trial evaluating an accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) protocol for Major Depressive Disorder (MDD). The study, involving 104 adult patients across eight sites, compared accelerated Deep TMS using intermittent theta burst stimulation to standard treatment. The accelerated protocol showed comparable efficacy with significant advantages: patients received five 10-minute sessions daily over six days plus eight continuation sessions, versus traditional daily sessions over six weeks. Key results showed depression score reductions of 18.9 points for accelerated treatment versus 19.9 for standard treatment, with response rates of 87.8% versus 87.5%. The accelerated group achieved median remission in 21 days compared to 28 days for standard treatment. The protocol demonstrated strong safety with no serious adverse events.

BrainsWay Ltd. (BWAY) announces its Gold Sponsorship of the Clinical TMS Society's 2025 Annual Meeting in San Diego from June 12-14. The company will showcase its Deep Transcranial Magnetic Stimulation technology through live demonstrations and new research presentations. Key highlights include a clinical education session presenting results from a multicenter RCT comparing standard and accelerated Deep TMS depression protocols. Notable research presentations will feature outcomes from a Phase IV Registry Study showing 49% success rate in smoking cessation using the H4 Coil, safety data from over 1,200 adolescent depression patients, and a third-party study on optimal H1 Coil positioning. The company will offer hands-on demonstrations of their Deep TMS system, highlighting its advantages over traditional figure-8 coil TMS.

BrainsWay Ltd. (BWAY) has announced a $5 million strategic equity investment in Stella MSO, LLC, a management services organization operating over 20 mental health clinics across the U.S. and Israel that have treated more than 30,000 patients. The investment will give BrainsWay a minority stake in Stella through a preferred, annually compounding security with a redemption mechanism. This move is part of BrainsWay's broader initiative to accelerate access to and awareness of innovative mental health treatments, particularly Deep TMS Therapy. The company is actively evaluating similar investments in other leading U.S. mental health providers. Stella's CEO Michael Gershenzon views the partnership as strategic for expanding access to transformative care.